Nivo-lution in Mesothelioma.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.See related article by Okada et al., p. 5485.

Keyphrases

clinical trial
phase ii
open label
transcription factor
combination therapy
double blind